System and method for bone loss assay
Disclosed are embodiments of a lateral flow test strip (LFTS) platform which measure osteocalcin (OC) and deoxypyridinoline (Dpd) in saliva to identify early indications of bone loss and minimize bone fracture risk associated with osteoporosis. The OC assay embodiments are based on the experimentally identified optimal markers which exhibit selectivity with very low false positives, and sensitivity relevant to clinical requirements. A prospective clinical study sampling of 20 patients demonstrated excellent correlation of OC in saliva with bone mineral density (BMD). Salivary OC and Dpd levels were validated with a standard commercial ELISA kit against serum (OC) and urine (Dpd).
1. A method for screening for osteoporosis comprising:
a. obtaining a saliva sample from a subject;
b. applying the saliva sample to a lateral flow test strip, wherein the strip comprises a conjugate pad deposited with a fluorescently labeled detector antibody, and at least one capture line reactive to osteocalcin;
c. placing the test strip in a fluorescent reader calibrated to quantitatively measure osteocalcin concentration at a given sample volume;
d. performing a screening diagnostic evaluation according to a quantitative measurement obtained from the reader;
wherein the at least one capture line comprises a capture antibody specific to osteocalcin, and a control line; wherein the capture antibody and the fluorescently labeled detector antibody pair are chosen from the group consisting of:
a. 940/939,
b. 11F8/939,
c. 2H9/939,
d. 940/H10,
e. 2H9/H10,
f. 940/3G8,
g. 11F8/3G8.
2. The method for screening for osteoporosis as in claim 1 , wherein the conjugate pad fluorescent reagent is a labeled detector antibody conjugated to fluorescent microparticles which is paired with a capture antibody immobilized on the membrane on one of the at least one capture line.